The big picture: Holifya has raised €2 million to expand its AI-powered GLP-1 obesity clinic in Milan.
Why it matters:
- Market Gap: Italy shows significantly lower adoption of GLP-1 drugs for obesity treatment, with less than 1% of eligible individuals utilizing them compared to over 4% in the UK.
- AI-Powered Care: Holifya’s AI-driven approach aims to personalize and optimize GLP-1-based obesity care, potentially improving patient outcomes and accessibility.
- Public Health Challenge: Addressing obesity through innovative solutions is critical for public health, reducing the burden of related chronic diseases.
How it works:
- Digital Clinic Model: Holifya operates an AI-powered digital clinic focused on GLP-1-based treatments for obesity.
- Geographic Expansion: The new funding will specifically support the expansion of its services within Milan, targeting the underserved Italian market.
- Personalized Treatment: The AI component likely assists in patient assessment, treatment planning, and monitoring to deliver tailored care.
The catch: The Italian market for GLP-1 drugs faces unique challenges, including potential regulatory hurdles, physician adoption rates, and public awareness. Holifya will need to navigate a competitive digital health landscape while educating both patients and healthcare providers on the benefits and proper use of AI-integrated GLP-1 therapies.
Key Facts
- Company: Holifya
- Amount: €2M
- Investor: CDP Venture Capital (lead)
- Sector: AI-powered Obesity Care
- Headquarters: Milan, Italy
